| abstract |
The present invention provides methods of treating Pneumocystis carinil, Glardia lamblia, and Cyrptosporidium paryum pneumonia in a subject in need of such treatment; the methods comprise administering to said subject a compound of Formula (I): (See Formula) wherein: R1 and R2 are each independently selected from the group consisting of H, C1-C6 alkyl, aryl, alkylaryl, aminoalkyl, aminoaryl , halogen, oxyalkyl, oxaryl, or oxarylalkyl; R3 and R4 are each independently selected from the group consisting of H, C1-C6 alkyl, oxyalkyl, alkylaryl, aryl, oxaryl, aminoalkyl, aminoaryl or halogen; and X and Y are located at the para or meta positions and are selected from the group consisting of H, C1-C6 alkyl, oxyalkyl, and (See Formula), wherein: each R3 is independently selected from the group consisting of H , C1-C6 alkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl or alkylaryl or two R5 groups together represent C2-C10 alkyl, hydroxyalkyl or alkylene; and R6 is H, hydroxy, C1-C6 alkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, cycloalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aryl or alkylaryl; or a pharmaceutically acceptable salt thereof; the compounds are administered in an amount effective to treat the condition; pi also includes novel compounds useful in the treatment of pneumonia caused by Pneumocystis carinil, as well as Giardia lamblia and Cryptosporidium paryum. |